BiosyentTSXV:RX -0.50%99 Dividend Yield % is 1.51% as of Jun. 26, 2026, which is 5% below its 10-year median of 1.59. GuruFocus rates TSXV:RX with a GF Score™ of 99/100 and a GF Value™ of C$16.11 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 516 Drug Manufacturers companies, Biosyent ranks worse than 59.69% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Biosyent is 1.51%.
The historical rank and industry rank for Biosyent's Dividend Yield % or its related term are showing as below:
TSXV:RX'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.53 Med: 1.59 Max: 2.03
Current: 1.51
During the past 13 years, the highest Dividend Yield of Biosyent was 2.03%. The lowest was 0.53%. And the median was 1.59%.
TSXV:RX's Dividend Yield % is ranked worse than 59.69% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.03
vs TSXV:RX: 1.51
During the past 12 months, Biosyent's average Dividends Per Share Growth Rate was 10.80% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 71.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Biosyent was 71.00% per year. The lowest was 71.00% per year. And the median was 71.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Biosyent (TSXV:RX) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Biosyent's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosyent Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biosyent's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Biosyent's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Biosyent Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
CAD 0.055000
2026-05-29
2026-05-29
2026-06-15
Cash Dividend
quarterly
CAD:CAD 1.000000
CAD 0.055000
2026-02-27
2026-02-27
2026-03-13
Cash Dividend
quarterly
CAD:CAD 1.000000
CAD 0.050000
2025-11-28
2025-11-28
2025-12-15
Cash Dividend
quarterly
CAD:CAD 1.000000
CAD 0.050000
2025-08-29
2025-08-29
2025-09-15
Cash Dividend
quarterly
CAD:CAD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Biosyent's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
0.21
/
13.93
=
1.51 %
Current Share Price is C$13.93. Biosyent's Dividends per Share for the trailing twelve months (TTM) ended in Today is C$0.21.
Biosyent's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
0.22
/
13.93
=
1.58 %
Current Share Price is C$13.93. Biosyent's Dividends per Share for the forward twelve months is calculated as C$0.055 * 4 = C$0.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosyent (TSXV:RX) has a Dividend Yield % of 1.51% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Biosyent and its competitors. This is near median its historical median of 1.59. Over the past decade, Biosyent's Dividend Yield % has ranged from 0.53 to 2.03. According to the industry distribution chart, Biosyent ranks #308 out of 516 companies in the Drug Manufacturers industry, placing it in the top 59.7%.
Is Biosyent's Dividend Yield % too high?
Biosyent's current Dividend Yield % of 1.51% is near median its 10-year median of 1.59. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 2.03. The Drug Manufacturers industry median Dividend Yield % is 2.03. Biosyent's value of 1.51% is 25.6% below this industry median. Based on the distribution chart, Biosyent ranks #308 out of 516 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biosyent has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Biosyent ranks #308 out of 516 companies for Dividend Yield %. This places Biosyent in the lower half of its industry. The industry median Dividend Yield % is 2.03. Biosyent's value of 1.51% is 25.6% below this benchmark. Historically, Biosyent's own Dividend Yield % has ranged from 0.53 to 2.03 over the past decade. While the company's 10-year median is 1.59 vs. the industry median of 2.03, Biosyent has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.03, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosyent's current Dividend Yield % of 1.51% is 25.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Biosyent and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosyent's current Dividend Yield % is 1.51%, which is near median its own 10-year median of 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (TSXV:RX) is currently considered Modestly Undervalued. The stock's GF Value™ is C$16.11, compared to a current price of C$13.93 — trading 13.5% below its estimated fair value. The current Dividend Yield % is 1.51%, which is near median its 10-year median of 1.59 and 25.6% below the Drug Manufacturers industry median of 2.03. Biosyent's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Biosyent (TSXV:RX), the current Dividend Yield % is 1.51% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosyent (TSXV:RX) Overvalued in 2026?
Based on GuruFocus' analysis, Biosyent stock appears to be undervalued.
The current stock price of C$13.93 is trading 13.5% below its estimated GF Value™ of C$16.11.
GuruFocus considers Biosyent to be Modestly Undervalued.
Key valuation signals for TSXV:RX:
Dividend Yield %: 1.51% (near median its 10-year median of 1.59)
GF Value™: C$16.11 vs. price of C$13.93 (13.5% below fair value)
Industry Position: 25.6% below the Drug Manufacturers median (#308 of 516)
No single metric tells the full story. See the TSXV:RX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
99GF Score
Get the complete analysis for TSXV:RX
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:RX has been successfully added to your 
